Brief: Metacrine Updates Met642 Clinical Development Milestone, Reports Q2 Results
12/08/2021 13:11
Aug 12 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE, INC. - BELIEVES IT HAS SUFFICIENT CAPITAL TO
FUND ITS
CURRENT OPERATING PLAN THROUGH 2022
Source text for Eikon: ID:nGNX2b5gyR
Further company coverage: MTCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions